Shanghai, China
Henlius, founded in 2010, has rapidly emerged as a key player in the biopharmaceutical sector, focusing on oncology. The company's slogan, "Reliable Quality · Affordable Innovation," encapsulates its commitment to delivering high-quality and cost-effective treatments to patients globally.
Headquartered in China, Henlius operates at the intersection of Biotechnology, Health Care, and Pharmaceutical industries. It serves over 950,000 patients across approximately 60 countries, emphasizing its expansive reach and impact.
The company's last major financial injection was a $156.00M venture round investment on 20 July 2018, backed by notable investors such as New China Capital Management, Loyal Valley Capital, CICC, and GreenTomato. Such investment underscores confidence in Henlius's innovative potential and scalability in the pharmaceutical industry.
